309 related articles for article (PubMed ID: 16086033)
1. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
Sagi Y; Driguès N; Youdim MB
Br J Pharmacol; 2005 Oct; 146(4):553-60. PubMed ID: 16086033
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
3. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
Weinstock M; Poltyrev T; Bejar C; Youdim MB
Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
[TBL] [Abstract][Full Text] [Related]
5. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
6. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Weinstock M; Bejar C; Wang RH; Poltyrev T; Gross A; Finberg JP; Youdim MB
J Neural Transm Suppl; 2000; (60):157-69. PubMed ID: 11205137
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
Sagi Y; Weinstock M; Youdim MB
J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
[TBL] [Abstract][Full Text] [Related]
8. Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats.
Poltyrev T; Gorodetsky E; Bejar C; Schorer-Apelbaum D; Weinstock M
Psychopharmacology (Berl); 2005 Aug; 181(1):118-25. PubMed ID: 15830235
[TBL] [Abstract][Full Text] [Related]
9. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
Weinstock M; Gorodetsky E; Poltyrev T; Gross A; Sagi Y; Youdim M
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):555-61. PubMed ID: 12787840
[TBL] [Abstract][Full Text] [Related]
10. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
[TBL] [Abstract][Full Text] [Related]
11. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
Yogev-Falach M; Bar-Am O; Amit T; Weinreb O; Youdim MB
FASEB J; 2006 Oct; 20(12):2177-9. PubMed ID: 16935943
[TBL] [Abstract][Full Text] [Related]
12. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Bar-Am O; Weinreb O; Amit T; Youdim MB
J Mol Neurosci; 2009 Feb; 37(2):135-45. PubMed ID: 18751929
[TBL] [Abstract][Full Text] [Related]
13. Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.
Luques L; Shoham S; Weinstock M
Exp Neurol; 2007 Aug; 206(2):209-19. PubMed ID: 17580085
[TBL] [Abstract][Full Text] [Related]
14. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
[TBL] [Abstract][Full Text] [Related]
15. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
[TBL] [Abstract][Full Text] [Related]
16. Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.
Moses D; Gross A; Finberg JP
Neuropharmacology; 2004 Jul; 47(1):72-80. PubMed ID: 15165835
[TBL] [Abstract][Full Text] [Related]
17. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
Finberg JP; Youdim MB
Neuropharmacology; 2002 Dec; 43(7):1110-8. PubMed ID: 12504917
[TBL] [Abstract][Full Text] [Related]
19. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Bar-Am O; Yogev-Falach M; Amit T; Sagi Y; Youdim MB
J Neurochem; 2004 Jun; 89(5):1119-25. PubMed ID: 15147504
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.
Liang YQ; Tang XC
Acta Pharmacol Sin; 2006 Sep; 27(9):1127-36. PubMed ID: 16923332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
